500 related articles for article (PubMed ID: 17147801)
1. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
2. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
[TBL] [Abstract][Full Text] [Related]
3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
5. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
6. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
7. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
8. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
9. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
Pouladi MA; Xie Y; Skotte NH; Ehrnhoefer DE; Graham RK; Kim JE; Bissada N; Yang XW; Paganetti P; Friedlander RM; Leavitt BR; Hayden MR
Hum Mol Genet; 2010 Apr; 19(8):1528-38. PubMed ID: 20097678
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
[TBL] [Abstract][Full Text] [Related]
11. A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
Chen S; Zhang XJ; Xie WJ; Qiu HY; Liu H; Le WD
CNS Neurosci Ther; 2015 Aug; 21(8):662-71. PubMed ID: 26122704
[TBL] [Abstract][Full Text] [Related]
12. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease.
Sutton LM; Sanders SS; Butland SL; Singaraja RR; Franciosi S; Southwell AL; Doty CN; Schmidt ME; Mui KK; Kovalik V; Young FB; Zhang W; Hayden MR
Hum Mol Genet; 2013 Feb; 22(3):452-65. PubMed ID: 23077216
[TBL] [Abstract][Full Text] [Related]
13. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.
Graham RK; Deng Y; Pouladi MA; Vaid K; Ehrnhoefer D; Southwell AL; Bissada N; Franciosi S; Hayden MR
J Huntingtons Dis; 2012; 1(2):243-60. PubMed ID: 25063333
[TBL] [Abstract][Full Text] [Related]
14. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR
Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983
[TBL] [Abstract][Full Text] [Related]
15. Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM; Warby SC; Hayden MR
Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
[TBL] [Abstract][Full Text] [Related]
16. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
[TBL] [Abstract][Full Text] [Related]
17. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
[TBL] [Abstract][Full Text] [Related]
18. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
Slow EJ; Graham RK; Osmand AP; Devon RS; Lu G; Deng Y; Pearson J; Vaid K; Bissada N; Wetzel R; Leavitt BR; Hayden MR
Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11402-7. PubMed ID: 16076956
[TBL] [Abstract][Full Text] [Related]
19. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.
Pouladi MA; Stanek LM; Xie Y; Franciosi S; Southwell AL; Deng Y; Butland S; Zhang W; Cheng SH; Shihabuddin LS; Hayden MR
Hum Mol Genet; 2012 May; 21(10):2219-32. PubMed ID: 22328089
[TBL] [Abstract][Full Text] [Related]
20. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Bailey CD; Rogers DA; Johnson GV; Hayden MR; Leavitt BR
J Neurochem; 2005 Oct; 95(1):210-20. PubMed ID: 16181425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
